Immunic Inc (IMUX)

$1.18

-0.09

(-7.09%)

Market is closed - opens 7 PM, 22 Apr 2024

Insights on Immunic Inc

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 48.4% return, outperforming this stock by 73.2%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 234.9% return, outperforming this stock by 325.8%

Performance

  • $1.18
    $1.27
    $1.18
    downward going graph

    0.0%

    Downside

    Day's Volatility :7.09%

    Upside

    7.09%

    downward going graph
  • $0.95
    $3.11
    $1.18
    downward going graph

    19.91%

    Downside

    52 Weeks Volatility :69.61%

    Upside

    62.06%

    downward going graph

Returns

PeriodImmunic IncSector (Health Care)Index (Russel 2000)
3 Months
2.16%
-0.4%
0.0%
6 Months
0.85%
8.5%
0.0%
1 Year
-24.84%
4.2%
-1.2%
3 Years
-90.86%
13.9%
-19.2%

Highlights

Market Capitalization
114.2M
Book Value
$0.64
Earnings Per Share (EPS)
-2.11
Wall Street Target Price
11.5
Profit Margin
0.0%
Operating Margin TTM
0.0%
Return On Assets TTM
-68.13%
Return On Equity TTM
-131.28%
Revenue TTM
0.0
Revenue Per Share TTM
0.0
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-99.1M
Diluted Eps TTM
-2.11
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.99
EPS Estimate Next Year
-0.92
EPS Estimate Current Quarter
-0.51
EPS Estimate Next Quarter
-0.45

Analyst Recommendation

Buy
    80%Buy
    20%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Immunic Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 874.58%

Current $1.18
Target $11.50

Technicals Summary

Sell

Neutral

Buy

Immunic Inc is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Immunic Inc
Immunic Inc
-14.49%
0.85%
-24.84%
-90.86%
-91.75%
Moderna, Inc.
Moderna, Inc.
-1.62%
26.13%
-28.15%
-35.32%
329.16%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-7.25%
10.93%
12.37%
77.79%
168.48%
Novo Nordisk A/s
Novo Nordisk A/s
-5.87%
27.44%
48.41%
234.91%
410.23%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-4.33%
8.96%
19.79%
79.09%
133.97%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Immunic Inc
Immunic Inc
NA
NA
NA
-0.99
-1.31
-0.68
NA
0.64
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.22
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
25.72
25.72
1.46
45.22
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
46.32
46.32
2.4
3.33
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
28.33
28.33
0.53
16.77
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Immunic Inc
Immunic Inc
Buy
$114.2M
-91.75%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$38.8B
329.16%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$98.1B
168.48%
25.72
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$550.4B
410.23%
46.32
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$101.7B
133.97%
28.33
36.68%

Institutional Holdings

  • RTW INVESTMENTS, LLC

    4.82%
  • Gratus Capital LLC

    2.16%
  • Omega Fund Management LLC

    1.99%
  • Vanguard Group Inc

    1.88%
  • Bvf Inc

    1.28%
  • UBS O'Connor LLC

    0.67%

Corporate Announcements

  • Immunic Inc Earnings

    Immunic Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

immunic, inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, crohn's disease, and psoriasis. its lead development program is imu-838, a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme dihydroorotate dehydrogenase, which is in phase 2 clinical development for treatment of ulcerative colitis and relapsing-remitting multiple sclerosis, as well as in phase 2 trial to treat crohn's disease. the company is also developing imu-935, an inverse agonist of rorgt; and imu-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. immu

Organization
Immunic Inc
Employees
77
CEO
Dr. Duane D. Nash J.D., M.B.A., M.D.
Industry
Pharmaceuticals: Major

FAQs